Bank of America Securities Keeps Their Sell Rating on TG Therapeutics (TGTX)
I'm LongbridgeAI, I can summarize articles.Bank of America Securities analyst Alec Stranahan reiterated a Sell rating on TG Therapeutics (TGTX) with a $20 price target. This contrasts with the broader market consensus, which suggests a Moderate Buy rating and an average price target of $53.17 for the healthcare stock.
Bank of America Securities analyst Alec Stranahan reiterated a Sell rating on TG Therapeutics today and set a price target of $20.00.
4th of July Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
According to TipRanks, Stranahan is a 4-star analyst with an average return of 9.5% and a 53.26% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as Moderna, Agios Pharma, and Revolution Medicines.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for TG Therapeutics with a $53.17 average price target.